Skip to main content

Home/ Medicine & Healthcare/ Group items tagged sBCC

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
avivajazz jazzaviva

Nonsurgical Treatment Options for Basal Cell Carcinoma | Review Article | Journal of Sk... - 0 views

www.hindawi.com/...571734

BCC sBCC studies pubs outcomes efficacy therapy therapies treatment options treatments

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Journal of Skin CancerVolume 2011 (2011), Article ID 571734, 6 pagesdoi:10.1155/2011/571734 © 2011 Mary H. Lien and Vernon K. Sondak.
avivajazz jazzaviva

Mohs surgery in sBCC following treatment with imiquimod 5% cream - 0 views

www.ncbi.nlm.nih.gov/...18569271

mohs aldara imiquimod cream sBCC BCC 2-year 1-year follow-up followup pubs abstract

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Eight of nine individuals, 89% (95% CI 56% to 97%) were histologically clear of sBCC at 52 weeks.
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinoma following successful treatment with... - 0 views

www.jle.com/...article.phtml

recurrence rate recurrences recurrence-rate BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies free fulltext free

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%. 
avivajazz jazzaviva

Imiquimod 5% cream for the treatment of superficia... [J Am Acad Dermatol. 2004] - PubM... - 0 views

www.ncbi.nlm.nih.gov/...15097956

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Composite clearance rates (combined clinical and histological assessments) for the 5 and 7x/week imiquimod groups were 75% and 73%, respectively. Histological clearance rates for the 5 and 7x/week imiquimod groups were 82% and 79%, respectively. Increasing severity of erythema, erosion, and scabbing/crusting was associated with higher clearance rates. CONCLUSION: Imiquimod appears to be safe and effective for the treatment of sBCC when compared with vehicle cream. The difference in clearance rates between the two imiquimod dosing groups was not significant. The 5x/week regimen is recommended.
avivajazz jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2005 Sep-Oct] - ... - 0 views

www.ncbi.nlm.nih.gov/...16172048

recurrence rate recurrences recurrence-rate BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
avivajazz jazzaviva

Aldara (tm) [imiquimod] Cream ~ Full Prescribing Information ~ FDA / Package Insert - 0 views

www.accessdata.fda.gov/...020723s020lbl.pdf

imiquimod aldara FDA approval sBCC BCC basal-cell-carcinoma basalcellcarcinoma prescribing fullprescribinginformation packageinsert full-prescribing-information FDA-approval

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    FDA-approval:  * Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults; maximum tumor diameter of 2.0 cm on trunk, neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured (1.2)
avivajazz jazzaviva

New Skin Cancer Treatment Approved - Skin Diseases, Conditions, Symptoms, and Procedure... - 0 views

www.medicinenet.com/...art.asp

imiquimod aldara FDA approval sBCC basal-cell-carcinoma basalcellcarcinoma BCC

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    79% of patients had no evidence of their sBCC at two years after finishing treatment.
avivajazz jazzaviva

Aldara ~ Prior Authorization Guideline - 0 views

www.prescriptionsolutions.com/...Guideline_3016.pdf

insurance medical preapproval priorauthorization prior-authorization authorization

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Superficial Basal Cell Carcinoma Aldara™ cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.  The histological diagnosis of superficial basal cell carcinoma should be established for other types of basal cell carcinomas, including nodular, morpheaform (fibrosing or sclerosing) types.
avivajazz jazzaviva

Imiquimod cream (Aldara) for superficial basal cell carcinoma: NPS - Better choices, Be... - 0 views

www.nps.org.au/...perficial_basal_cell_carcinoma

imiquimod aldara sBCC BCC basalcellcarcinoma cream therapy treatment

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Imiquimod cream (Aldara) for superficial basal cell carcinoma
avivajazz jazzaviva

Use of 5% imiquimod cream in the treatment of faci... [Australas J Dermatol. 2006] - Pu... - 0 views

www.ncbi.nlm.nih.gov/...16866996

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    We found that 5% imiquimod cream is an effective treatment option for superficial and nodular basal cell carcinomas, giving a clearance rate of 89.5% at an average of 39 months of follow up.
avivajazz jazzaviva

21152128[PMID] - PMC result - 0 views

www.ncbi.nlm.nih.gov/pmc

images photographs photo photos photograph nodular nodulo-cystic BCC sBCC basal-cell-carcinoma basalcellcarcinoma skincancer skin-cancer

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Nodulo-cystic BCC. [Image, Photograph] Venura Samarasinghe, et al. J Skin Cancer. 2011;2011:328615.
avivajazz jazzaviva

Management of superficial basal cell carcinoma: focus on imiquimod ~ 2009 - 0 views

www.ncbi.nlm.nih.gov/...ccid-2-065.pdf

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies free fulltext freefulltext pdf

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
  • avivajazz jazzaviva on 24 Jul 11
     
    Raasch B. Clinical, Cosmetic and Investigational Dermatology. 9 June 2009.  There is reasonable evidence that the use of imiquimod for small (<2 cm) superficial BCC that occur other than on the face provides  outcomes only marginally less satisfactory t
avivajazz jazzaviva

Treatment of Cutaneous Tumors with Topical 5% Imiquimod Cream | Alessi SS, et al | CLIN... - 0 views

www.ncbi.nlm.nih.gov/...cln_64p961.pdf

BCC sBCC basal-cell-carcinoma basalcellcarcinoma treatment treatments skincancer skin-cancer therapy pubmed pubs trials clinicaltrials abstracts therapies imiquimod aldera aldara study studies pdf

shared by avivajazz jazzaviva on 24 Jul 11 - No Cached
    • avivajazz jazzaviva
      avivajazz jazzaviva on 24 Jul 11
       
      For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
  • avivajazz jazzaviva on 24 Jul 11
     
    For patients without comorbidities, our study revealed good cure rates for superficial BCC and superficial/nodular BCC (88% and 85%, respectively). Nodular and aggressive BCC and Bowen's disease exhibited lower cure rates (50%, 50%, and 57%, respectively). I
1 - 20 of 55 Next › Last »
Showing 20▼ items per page